0000000000934243
AUTHOR
S Magrini
showing 5 related works from this author
Lista Rossa IUCN della Flora Italiana. 1. Policy Species e altre specie minacciate
2013
As part of the Mediterranean global biodiversity hotspot, the Italian flora is particularly rich of species, many of them endemic to restricted territories. In some areas of Italy endemic plant species reach very high percentages, between 13% and 20% of the local flora. However, plant diversity in the Mediterranean Basin is facing several threats due to changes of the current socio-economic dynamics. Italy is not an exception and urgent conservation measures are needed to halt the loss of biodiversity and preserve the numerous threatened species. This volume is the output of a project started in 2012, funded by the Italian Ministry of Environment for the Protection of Land and Sea and carri…
Nuove liste rosse della flora italiana
2013
Vengono presentate le nuove liste rosse per la Flora Italiana incluse le piante superiori, le briofite ed i funghi
RIBES, la rete italiana delle banche del germoplasma: i primi 10 anni di attività per la conservazione ex situ della flora spontanea.
2016
Il lavoro presenta le attività di RIBES, la rete italiana delle banche del germoplasma, relativamente ai primi 10 anni di azioni di conservazione della biodiversità vegetale su scala nazionale.
The conservation of the Italian Crop Wild Relatives in the RIBES seed-banks: first data to establish national inventories and conservation priorities.
2016
The authors present the updated results of such census in the Italian Seed Bank Network for native species conservation (RIBES) with an analysis of the contribution to the conservation of the Italian FAO priority CWR. Finally, a national priority list for conservation of CWRs was drawn up and proposed here.
The waiting time for prostate cancer treatment in Italy: analysis from the PROS-IT CNR Study.
2022
Background Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certain indication about the maximum waiting time (WT) acceptable for treatment beginning and the impact on oncological and functional outcomes has not been well established. Methods Data from the National Research Council PCa monitoring multicenter project in Italy (Pros-IT CNR) were prospectively collected and analyzed. WT was defined as the time from the bioptical diagnosis of PCa to the first treatment received. Patients were divided in two groups, using a time frame of 90 days. Quality of life was measured through the Italian version of the University of California Los Angeles-Pros…